- 在国内听小道消息，从动车事故到王立军 (ZT) [2012/05]
- 对八九六四的认真反思，一不得不读的好文 (ZT) [2013/06]
- 昨天说他是＂奴才＂，今更正为＂洋奴才＂ [2010/07]
- 中国不应该计划生育吗？ by 米笑 [2011/12]
- 林书豪事件后，哪些华人反应过激 (ZT) [2012/02]
- 也谈6.4，支持小平 [2009/05]
- 美国公司文化体验之一 (记我的两个70后同事) [2009/05]
- 新中国风风雨雨走过６１年，值此大喜的日子，作为海外华人，今天来＂酸葡萄＂一下 [2010/10]
- 看看美国公校里怎样教乘法 [2009/02]
- 质疑［一个统一过中国的领导人，肯定不是人民的公敌。］ [2010/04]
- 华人是白人还是黑人？美国最高法院回答你 (ZT) [2011/04]
- 智取小偷－－驾校里的故事 [2009/05]
- 周燕霞是政客吗？ [2009/03]
- 一转身，交了个朋友；再一转身，又交了个朋友，还得了份工作 [2009/04]
- 母亲的诗 [2009/03]
- 村里建了“忠烈祠” [2009/03]
- 我的兄弟姐妹 [2009/04]
- 儿时回忆－－斗风筝 [2009/02]
- 爆破班上课了 [2009/04]
- 大蛇的传说 [2009/05]
- 文革中的母亲 [2009/05]
当然，这也不能都怪 FDA了...
和法律不是万能一样，政府也不是万能的。
一句名言：" It ’ s not about what you did, it ’ s about what you can prove."
一个新药要上市，必得证明１）有疗效，２）副作用小。
FDA 的正常批准程序是要求药厂提供两个正面的测试报告。这里面的可操作空间就很大。
有规定，FDA请的鉴定专家，不得与药厂有连带的经济利益。但是药厂神通广大，令FDA对某些专家，放弃(waiver)了这一规定。
螳螂捕蝉，黄雀在后。
如果说病人是蝉，医生，专家，政府官员是螳螂，那拿大头的是药厂就是黄雀了：
(too long to list them all)
......
Critics say the program is actually a scam set up with state policy makers to make sure the expensive psychiatric drugs remain on the Medicaid covered drug lists instead of being placed on the lists that require prior authorization.
Ben Hansen, a member of the Michigan Department of Community Health Recipient Rights Advisory Committee, has been investigating the atypical makers' involvement in the Medicaid programs in Michigan and other states and says that none of the states with CNS contracts require prior authorization for the atypical drugs.
Mr Hansen published some of the results of his investigation in the Spring 2007 Newsletter of the International Center for the Study of Psychiatry and Psychology. By using the FOIA, Mr Hansen says he has obtained nearly a thousand pages of documents which show that Medicaid is being "milked like a huge cash cow."
According to Allen Jones, a former Medicaid fraud investigator, the long list of corporate sponsors for CNS includes: AstraZeneca, Janssen, Bristol-Myers, Pfizer, Lilly and Glaxo.
Back in 2002, Mr Jones found that Janssen was using CNS to funnel payments to state officials who controlled the Medicaid preferred drug lists in Pennsylvania to ensure that Risperdal would be on the list.
For his part, the leader of the Minnesota CNS program, Dr Adson, was paid $5,200 by AstraZeneca, Glaxo shows $331,947 going to him, and Pfizer gave him $1,000, in 2004 alone.
Also, in 2006, Dr Adson received $83,325 from AstraZeneca and roughly $6,100 from Bristol-Myers, according to a compilation of disclosure forms by the Pioneer Press and the watchdog group Public Citizen.